Sickle Cell Disease

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Participate in a Study

Seattle Cancer Care Alliance is committed to developing new therapies and participating in clinical studies.

The success in treating illness is the best example of success through collaboration. In clinical studies, researchers prescribe promising treatment regimens, monitor the patients responses carefully, and compare this treatment to standard treatment.

For sickle cell disease, bone marrow transplant is currently the only curative therapy. Beginning with seminal studies led by Fred Hutchinson Cancer Research Center, researchers have documented disease-free survival of around 85 percent and overall survival around 95 percent in hundreds of children with matched sibling donors. Unfortunately, fewer than one in five children with SCD have a matched sibling and unrelated donor transplantation in SCD has met with less success. Outcomes in adults with SCD also have been less successful due to both disease- and transplant-related mortality. SCCA currently has several protocols aimed at improving outcomes for those with SCD.

For an overview of what happens in clinical trials, read our Patient Guide to Clinical Trials, especially the section on Children & Clinical Trials.

To find clinical trials for which your child may be eligible, ask your child’s healthcare team.

New Treatment Research

In 2007 two Fred Hutchinson Cancer Research Center researchers received a $23.7 million grant (awarded to Seattle Children's Hospital Research Institute) to support the Northwest Genome Engineering Consortium from the National Institutes of Health that will fund the development of new methods for gene repair thought to be helpful in treating diseases like sickle cell disease. Read more about this grant.